

PHARMING ANNUAL SHAREHOLDER'S MEETING

Leiden, The Netherlands, April 15, 2009. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) has provided an update on its product, financial and corporate developments during the Annual Meeting of Shareholders (AGM) today.

During the meeting, the Company confirmed its strategy to become an international specialty pharmaceutical company. This includes the development of therapeutic products for significant medical needs in orphan disease indications and for indications with serious unmet medical needs in larger markets in a second phase, Rhucin being the first example. Pharming will submit the dossier for the European Marketing Authorisation Application of Rhucin® for acute attacks of Hereditary Angioedema in September 2009. In addition, the product is under development for additional indications in the field of kidney transplantations. Products under development following this same strategy are Prodarsan®, expected to enter full clinical development later this year and recombinant human fibrinogen, currently in pre-clinical development.

While the current liquidity position of Pharming is sufficient for its operational development efforts into 2010, the Company continues to look at additional financing opportunities to further improve its financial position. Today's announcement of the standby equity agreement with Yorkville Advisors is a first example of such financing activities. With the earlier announced agreements with its bondholders on the cancellation of convertible bonds at favourable terms for the Company and the two milestone payments of € 10 million in total expected from Aslan later this year, Pharming is confident about its prospects for 2009 and 2010.

Following the appointment of Mr. Sijmen de Vries, Mr Francis J. Pinto stayed on as Non-Executive Chairman of the Management Board to ensure a smooth transition. He retires as of today. As part of the transition plan, a number of task forces were put in place, which will be discontinued. At the AGM, the majority of the Shareholders voted in favour of the proposed amendments to the remuneration policy and the option arrangements for the Board of Management of Pharming (BOM), the participation of the Board of Supervisory Directors (BOSD) in Pharming's 2009 Long Term Incentive Plan the appointment of Mr. A. de Winter and Mr. J. Ernst as members of the BOSD and the appointment of PricewaterhouseCoopers as new auditor.

"We are most grateful to Mr. Pinto and the remarkable turnaround of Pharming under his leadership. Pharming could not have reached its current stage without him," commented Mr. Blaak, Chairman of Pharming's Supervisory Board. "I would also like to thank Mr. Veltman, who retired from the BOSD per December 1, 2008. He has served on the Board for almost seven years including a few years as Chairman and made many valuable contributions during this period. I would like to welcome Messr. de Winter and Ernst as new members of the Supervisory Board. Mr. de Winter's extensive financial experience and Mr. Ernst's extensive senior level experience in the field of pharmaceutical development and marketing, are important reinforcements of Pharming's Board of Supervisory Directors."

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan® for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, <http://www.pharming.com>.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 400